Prosecution Insights
Last updated: October 02, 2026
Application No. 18/574,883

PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR

Non-Final OA §102
Filed
Dec 28, 2023
Priority
Jun 29, 2021 — JP 2021-107743 +1 more
Examiner
HUI, SAN MING R
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kyoto University
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
2m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
784 granted / 1317 resolved
-0.5% vs TC avg
Strong +20% interview lift
Without
With
+20.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
44 currently pending
Career history
1352
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
47.1%
+7.1% vs TC avg
§102
7.5%
-32.5% vs TC avg
§112
20.4%
-19.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1317 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-16 are pending. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-16 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2019/208812 (from IDS filed 12/28/2023, English equivalent US 11,548,882 (‘882). ‘882 teaches the herein claimed compounds of formula (1), (1A) and (2) and the corresponding composition (see col. 3, line 29 bridging col. 6, line 41, col. 19, line 1 bridging col. 27, line 50). The intended use of the instant composition does not lend patentable weight to the claims directed to composition. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAN MING R HUI whose telephone number is (571)272-0626. The examiner can normally be reached Mon - Fri 9:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAN MING R HUI/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Dec 28, 2023
Application Filed
Mar 02, 2026
Non-Final Rejection mailed — §102
Jun 02, 2026
Response Filed
Jun 02, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734179
PROGESTERONE FORMULATION TO TRIGGER OVULATION AND PROVIDE LUTEAL PHASE SUPPORT
4y 2m to grant Granted Sep 15, 2026
Patent 12735448
CRYSTAL FORM OF 3-HYDROXY-5-PREGNANE-20-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 1m to grant Granted Sep 15, 2026
Patent 12723047
HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
3y 4m to grant Granted Sep 01, 2026
Patent 12714104
COMPOSITION FOR CONTROLLING FLYING PEST INSECTS
2y 11m to grant Granted Aug 25, 2026
Patent 12708628
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MOTION SICKNESS AND EMESIS
2y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
80%
With Interview (+20.1%)
2y 11m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1317 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month